IF1抑制结直肠癌转移的机制
创作:爱的抉择 审核:szx 2019年12月30日
  • ATP合成酶抑制剂1(IF1)在多种肿瘤高表达,促进代谢重编程和癌症进展;
  • 然而在结直肠癌患者中,IF1的高表达与较低的复发率、较高的总生存期及无病生存期相关;
  • 与高表达IF1的结肠癌细胞相比,IF1敲低导致细胞具有更强的侵入性、致瘤潜能及转移潜能;
  • 机制上,IF1敲低导致cFLIP介导的对细胞失巢凋亡的抵抗增加,以增强癌症细胞的转移潜能;
  • IF1敲低的细胞形成肿瘤球状体,促进其逃避NK细胞的免疫监视。
主编推荐语
szx
来自Cancers上发表的一项最新研究,发现与其它肿瘤不同,在结直肠癌中,ATP合成酶抑制剂1(IF1)的高表达与较低的复发率、较长的总生存期及无病生存期相关。机制上,IF1抑制了cFLIP介导的对肿瘤细胞失巢凋亡的抵抗作用,以抑制肿瘤细胞的转移,而IF1低表达的肿瘤细胞可形成球状体以逃避NK细胞的免疫监视。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Cancers [IF:6.126]

Overexpression of Mitochondrial IF1 Prevents Metastatic Disease of Colorectal Cancer by Enhancing Anoikis and Tumor Infiltration of NK Cells

线粒体IF1的高表达通过增加失巢凋亡和NK细胞的肿瘤浸润以预防结直肠癌转移

10.3390/cancers12010022

2019-12-19, Article

Abstract & Authors:展开

Abstract:收起
Increasing evidences show that the ATPase Inhibitory Factor 1 (IF1), the physiological inhibitor of the ATP synthase, is overexpressed in a large number of carcinomas contributing to metabolic reprogramming and cancer progression. Herein, we show that in contrast to the findings in other carcinomas, the overexpression of IF1 in a cohort of colorectal carcinomas (CRC) predicts less chances of disease recurrence, IF1 being an independent predictor of survival. Bioinformatic and gene expression analyses of the transcriptome of colon cancer cells with differential expression of IF1 indicate that cells overexpressing IF1 display a less aggressive behavior than IF1 silenced (shIF1) cells. Proteomic and functional in vitro migration and invasion assays confirmed the higher tumorigenic potential of shIF1 cells. Moreover, shIF1 cells have increased in vivo metastatic potential. The higher metastatic potential of shIF1 cells relies on increased cFLIP-mediated resistance to undergo anoikis after cell detachment. Furthermore, tumor spheroids of shIF1 cells have an increased ability to escape from immune surveillance by NK cells. Altogether, the results reveal that the overexpression of IF1 acts as a tumor suppressor in CRC with an important anti-metastatic role, thus supporting IF1 as a potential therapeutic target in CRC.

First Authors:
Lucía González-Llorente

Correspondence Authors:
José M Cuezva

All Authors:
Lucía González-Llorente,Fulvio Santacatterina,Ana García-Aguilar,Cristina Nuevo-Tapioles,Sara González-García,Zuzana Tirpakova,María Luisa Toribio,José M Cuezva

评论